Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 9/2016

01-09-2016 | Original Research Article

Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies

Authors: Akshanth R. Polepally, Sven Mensing, Amit Khatri, Denise Beck, Wei Liu, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta

Published in: Clinical Pharmacokinetics | Issue 9/2016

Login to get access

Abstract

Background and Objectives

Paritaprevir is a direct-acting antiviral agent that is a component of approved multidrug regimens used in the treatment of hepatitis C virus (HCV) infection. A population pharmacokinetic model for paritaprevir was developed using data from formulation, bioavailability, and drug–drug interaction studies that evaluated the pharmacokinetics of paritaprevir (coadministered with ritonavir to enhance exposure) with or without ombitasvir and/or dasabuvir at different paritaprevir dose levels.

Methods

A non-linear mixed-effects modeling approach was applied to data from 12 phase I, single- and multiple-dose studies that enrolled a total of 369 healthy volunteers. Age, sex, race, ethnicity, body weight, body surface area, body mass index, and baseline creatinine clearance were evaluated as covariates during model development. In addition, the influences of dose, formulation, and concomitant medications (e.g. ombitasvir and dasabuvir) on paritaprevir bioavailability were included in the model.

Results

A two-compartment model with first-order absorption and elimination optimally described paritaprevir plasma concentration–time data. Paritaprevir bioavailability was formulation- and dose-dependent, and increased supraproportionally. The accumulation of paritaprevir was 1.57-fold on repeated dosing compared with the first dose. Coadministration of dasabuvir increased paritaprevir bioavailability by 59 %; however, ombitasvir coadministration did not affect the pharmacokinetic profile of paritaprevir. No subject-specific covariate influenced the paritaprevir pharmacokinetics. The pharmacokinetic model was robust in bootstrap evaluations and was consistent with observed data based on diagnostic goodness-of-fit plots and visual predictive checks.

Conclusion

The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV.
Appendix
Available only for authorised users
Literature
1.
Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87.CrossRefPubMed
2.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.CrossRefPubMed
3.
4.
Gentile I, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014;21:3261–70.CrossRefPubMed
5.
6.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(359–65):e1.PubMed
7.
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRefPubMed
8.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed
9.
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–32.CrossRefPubMed
10.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed
11.
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.CrossRefPubMed
12.
Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–97.CrossRefPubMed
13.
Menon R, Klein CE, Podsadecki T, Chiu Y, Dutta S, Awni W, et al. Pharmacokinetics and tolerability of paritaprevir, a direct-acting viral agent for HCV treatment, with and without ritonavir in 2 phase 1 studies. Br J Clin Pharmacol. 2015. doi:10.​1111/​bcp.​12873.
14.
Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505–11.CrossRefPubMed
15.
Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug–drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20–9.CrossRefPubMed
16.
17.
Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug–drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clinical Pharm Drug Dev. 2016 Jan 24;. doi:10.​1002/​cpdd.​246.
18.
Menon R, Klein C, Podsadecki T, Xiong J, Dutta S, Awni W, et al. Pharmacokinetics, safety and tolerability following multiple dosing of polymerase inhibitor, ABT-333 and protease inhibitor, ABT-450 with ritonavir. Presented at the 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. 27–28 Jun 2012, Cambridge, MA.
19.
Menon R, Kapoor M, Dumas E, Badri P, Campbell A, Giulati P, et al. Multiple-dose pharmacokinetics and safety following coadministration of ABT-450/r, ABT-267 and ABT-333 in Caucasian, Japanese and Chinese subjects [abstract 1497]. Hepatol Int. 2013;7:400.CrossRef
20.
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.CrossRefPubMedPubMedCentral
21.
Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.CrossRefPubMed
22.
Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S. Mechanistic understanding of the non-linear pharmacokinetics and inter-subject variability of simeprevir: A PBPK-guided drug development approach. Clin Pharmacol Ther. 2016;99:224–34.CrossRefPubMed
23.
Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59:806–13.PubMed
24.
25.
Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res. 2013;30:1050–64.CrossRefPubMed
26.
Li Y, Zhou J, Ramsden D, Taub ME, O'Brien D, Xu J, et al. Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation. Drug Metab Dispos. 2014;42:384–93.CrossRefPubMed
27.
Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, et al. Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies. J Hepatol. 2015;62(suppl 2):S644.CrossRef
28.
29.
Mensing S, Polepally A, König D, Khatri A, Liu W, Podsadecki T, et al. Population pharmacokinetics of ABT-450, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection [abstract T-007]. J Pharmacokinet Pharmacodyn. 2014;41:S42.
Metadata
Title
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies
Authors
Akshanth R. Polepally
Sven Mensing
Amit Khatri
Denise Beck
Wei Liu
Walid M. Awni
Rajeev M. Menon
Sandeep Dutta
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 9/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-016-0385-4

Other articles of this Issue 9/2016

Clinical Pharmacokinetics 9/2016 Go to the issue

Review Article

Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective

Review Article

Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy

Current Opinion

Pharmacokinetics of Melatonin: The Missing Link in Clinical Efficacy?

Review Article

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy

Original Research Article

Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium

Original Research Article

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients